BNP Paribas Financial Markets Grows Position in Catalent, Inc. (NYSE:CTLT)

BNP Paribas Financial Markets lifted its stake in shares of Catalent, Inc. (NYSE:CTLT - Free Report) by 154.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 216,311 shares of the company's stock after acquiring an additional 131,360 shares during the quarter. BNP Paribas Financial Markets owned about 0.12% of Catalent worth $12,211,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Catalent by 1.8% in the third quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company's stock valued at $931,909,000 after buying an additional 365,648 shares in the last quarter. Capital World Investors increased its holdings in shares of Catalent by 6.1% during the fourth quarter. Capital World Investors now owns 19,079,994 shares of the company's stock worth $857,264,000 after purchasing an additional 1,098,474 shares during the period. Nomura Holdings Inc. lifted its position in Catalent by 149.4% during the fourth quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company's stock worth $516,126,000 after purchasing an additional 6,881,914 shares during the period. Cadian Capital Management LP boosted its stake in Catalent by 14.3% in the fourth quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company's stock valued at $272,473,000 after buying an additional 759,600 shares in the last quarter. Finally, Capital International Investors grew its holdings in Catalent by 1.2% during the 4th quarter. Capital International Investors now owns 2,994,467 shares of the company's stock worth $134,541,000 after acquiring an additional 34,856 shares during the last quarter.

Catalent Stock Performance

Shares of CTLT stock traded up $0.13 during trading hours on Wednesday, hitting $57.43. 3,946,257 shares of the company were exchanged, compared to its average volume of 2,208,608. The firm has a fifty day simple moving average of $55.68 and a 200 day simple moving average of $54.66. Catalent, Inc. has a 52-week low of $31.80 and a 52-week high of $60.20. The company has a current ratio of 2.51, a quick ratio of 1.77 and a debt-to-equity ratio of 1.37. The stock has a market capitalization of $10.39 billion, a price-to-earnings ratio of -9.41, a P/E/G ratio of 2.36 and a beta of 1.16.

Catalent (NYSE:CTLT - Get Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by ($0.36). Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. The business had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.11 billion. Research analysts predict that Catalent, Inc. will post -0.17 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Matti Masanovich sold 2,993 shares of the business's stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $56.74, for a total value of $169,822.82. Following the completion of the sale, the chief financial officer now directly owns 33,871 shares of the company's stock, valued at approximately $1,921,840.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Matti Masanovich sold 2,993 shares of the stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $56.74, for a total transaction of $169,822.82. Following the sale, the chief financial officer now owns 33,871 shares in the company, valued at $1,921,840.54. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Ricky Hopson sold 1,401 shares of the stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total value of $76,018.26. Following the sale, the insider now owns 20,617 shares of the company's stock, valued at approximately $1,118,678.42. The disclosure for this sale can be found here. Company insiders own 0.31% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on CTLT. StockNews.com initiated coverage on shares of Catalent in a report on Monday. They set a "sell" rating on the stock. Stephens restated an "equal weight" rating and set a $63.50 target price on shares of Catalent in a report on Thursday, April 4th. Finally, Barclays increased their target price on Catalent from $47.00 to $63.00 and gave the company an "equal weight" rating in a research note on Friday, June 28th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $55.65.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.